Professional Marketing briefs: April 2012

Share this article:
Professional Marketing briefs: April 2012
Professional Marketing briefs: April 2012
GlaxoSmithKline and Daiichi ­Sankyo announced they will  team up to create Japan's largest vaccine company. The joint effort will be a 50-50 partnership, with an initial investment of at least ¥100,000,000 ($1.2 million) in seed money, according to a GSK statement. The two companies will distribute vaccines for HPV, rotavirus and measles rubella, among others.

Columbia Laboratories is reducing its headcount by 10, leaving it with 14 employees. The announcement follows the FDA's rejection of the company's progesterone vaginal 8% gel, intended to reduce the risk of pre-term birth. An approval would have meant a $30 million commercial launch payment from Watson Pharmaceuticals, which has the rights to the gel.

Eli Lilly announced the opening of offices with 200 research and manufacturing jobs to fill at its Kinsale campus in County Cork, Ireland (above). The jobs are part of the company's €330 million ($435 million) investment in a campus currently dedicated to small-molecule manufacturing. The investment will expand the site's footprint so that it could be the launch pad for the pharmaceutical company's biologics pipeline.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?